DESCRIPTION (provided by applicant): This application is intended to provide outstanding mentorship and a supportive laboratory environment to foster the development of Chinweike Ukomadu, M.D., Ph.D., towards a career as an independent scientist. The candidate has completed graduate studies and published several papers in the field of ion channel physiology. Following clinical training in internal medicine and gastroenterology he returned to the laboratory to study mechanisms of cell cycle regulation.
The proposed research will be carried out in the laboratory of Anindya Dutta, M.D., Ph.D., an internationally recognized investigator in the area of cell cycle regulation. Dr. Dutta's record in mentoring numerous junior scientists as they transitioned to careers as principal investigators provides an ideal setting for implementation of the goals of this proposal. Dr. Dutta's laboratory has extensive expertise in cell biological, biochemical, and genetic methodologies related to cell cycle studies. Seminars, conferences, and collegial interactions within the Departments of Pathology and Internal Medicine at Brigham and Women's Hospital will offer additional opportunity for scientific and career development.
This proposal outlines detailed studies aimed at further understanding the regulation of cyclin dependent kinase 2 (Cdk2), a key enzyme required for progression through the cell cycle. The studies will be carried out using established cancer cell lines. In preliminary studies, mevastatin, a cholesterol lowering agent, inhibited Cdk2 by preventing activating phosphorylation. The specific aims are: 1) to determine the molecular mechanism by which mevastatin inhibits the activation of Cdk2; 2) to show that cyclin H:cdk7, which has been felt to be essential for activation of Cdk2, is not required in some cancer cell lines; and 3) to elucidate the events underlying the inability of p21 to inhibit Cdk2 in some cancer cells.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
848
DUNS Number
030811269
UEI
QN6MS4VN7BD1
Project Start Date
15-September-2003
Project End Date
30-June-2008
Budget Start Date
01-July-2005
Budget End Date
30-June-2006
Project Funding Information for 2005
Total Funding
$133,920
Direct Costs
$124,000
Indirect Costs
$9,920
Year
Funding IC
FY Total Cost by IC
2005
National Institute of Diabetes and Digestive and Kidney Diseases
$133,920
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5K08DK067240-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5K08DK067240-03
Patents
No Patents information available for 5K08DK067240-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5K08DK067240-03
Clinical Studies
No Clinical Studies information available for 5K08DK067240-03
News and More
Related News Releases
No news release information available for 5K08DK067240-03
History
No Historical information available for 5K08DK067240-03
Similar Projects
No Similar Projects information available for 5K08DK067240-03